Effects by androgen suppression with luteinizing hormone on cognitive functions in men treated for cancer of prostate;Effet de la suppression androgénique par agonistes de la LH-RH sur les fonctions cognitives de patients atteints de cancer de prostate

Progres en Urologie

Volumn 19, Issue 1, 2009, Pages 47-53

  Nedelec, C ^a,d   Ragot, S ^b,d   Irani, J ^c,d   Pires, C ^c,d   Gil, R ^d   Dore B ^c,d  

^a centre hospitalier de la Rochelle   (France)

^b POITIERS UNIVERSITY HOSPITAL   (France)

^c University of Poitiers   (France)

^d UNIVERSITÉ DE POITIERS   (France)

Author keywords

Androgen deprivation; Cognitive changes; Prostate cancer

Indexed keywords

ANTIANDROGEN; DRUG DERIVATIVE; GONADORELIN;

ADENOCARCINOMA; AGED; ARTICLE; COGNITION; COMPARATIVE STUDY; DRUG EFFECT; HUMAN; MALE; MEMORY; PROSPECTIVE STUDY; PROSTATE TUMOR;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; COGNITION; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; MEMORY; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS;

EID: 58149190015     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.purol.2008.09.056     Document Type: Article

References (32)

1. Huggins C. Endocrine control of prostatic cancer. Science 97 (1943) 541-544
2. Soulié M., Beuzeboc P., Cornud F., Eschwège P., Gaschignard N, and et les membres du sous comité cancer de prostate du Comité de cancérologie de l'association française d'urologie. Prog Urol 17 (2007) 1157-1230
3. Bolla M., Gonzalez D., Warde P., Dubois J.B., Mirimanoff R.O., Storme G., et al. Improved survival in patients with locally advanced prostate cancer treated with radiothetarpy and goserilin. N Engl J Med 337 (1997) 295-300
4. ®) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression. Urology 58 (2001) 146-151
5. Messing E.M., Manola J., Yao J., Kiernan M., Crawford D., Wilding G., et al., Eastern Cooperative Oncology Group study EST 3886. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 4 (2006) 20-21
6. Milbank A.J., Dreicer R., and Klein E.A. Hormonotherapy for prostate cancer: primum non nocere. Urology 60 (2002) 738-741
7. Sprenkle P.C., and Fisch H. Pathologic effects of testosterone deprivation. Curr Opin Urol 17 (2007) 424-430
8. Sharifi N., Gulley J.L., and Dahut W.L. Androgen deprivation therapy for prostate cancer. JAMA 294 (2005) 238-244
9. Keating N.L., O'Malley J., and Smith M.R. Diabete and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 24 (2006) 4448-4456
10. Green H.J., Pakenham K.I., Headley B.C., Yaxley J., Nicol D.L., Mactaggart P.N., et al. Altered cognitive function in men treated for prostate cancer with luteinizing hormone-releasing hormone analogues and cyproterone acetate: a randomized controlled trial. BJU Int 90 (2002) 427-432
11. Weiland N.G., Orikasa C., Hayashi S., and Mc Ewen B.S. Distribution and hormone regulation of estrogen receptor immunoreactive cells in the hippocampus of male and females rats. J Comp Neurol 388 (1997) 603-612
12. Beer T.M., Bland L.B., Bussiere J.R., Neiss M.B., Wersinger E.M., Garzotto M., et al. Testosterone loss and estradiol administration modify memory in men. J Urol 175 (2006) 130-135
13. Folstein M.F., Folstein S.E., and Mac Hugh P.R. "Mini-Mental State". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12 (1975) 189-198
14. Mac Nair DM, Kahn RJ. Self assessment of cognitive deficits. In: T Crook et al., editors. Assesment in geriatric psychopharmacology 1983. p. 137-43.
15. Grober E., Buschke H., Crysta H., Bang S., and Dresner R. Screening for dementia by memory testing. Neurology 38 (1988) 900-903
16. Rey A. Test de copie d'une figure complexe : manuel (1959), Les Éditions du Centre de psycholgie Appliquée, Paris
17. Reitan R.M. The relation of the trail making test to organic damage. J Consult Psychol 19 (1955) 393-394
18. Wechsler D. Wechsler Adult Intelligence Scale. 3rd ed (1997), The Psychological Corporation, San Antonio, TX
19. e ed (2000), Les Éditions du Centre de Psychologie Appliquée, Paris
20. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-9.
21. Marin R.S., Biedrzycki R.C., and Firinciogullari S. Reliability and validity of the Apathy Evaluation Scale. Psychiatry Res 38 (1991) 143-162
22. Almeida O.P., Waterreus A., Spry N., Flicker L., and Martins R.N. One year follow-up of the association between chemical castration hormones, beta-amyloid, memory and depression. Psychoneuroendocrinology 29 (2004) 1071-1081
23. Salminen E., Portin R., Korpela J., Backman H., Parvinen L.M., Helenius H., et al. Androgen deprivation and cognition in prostate cancer. Br J Cancer 89 (2003) 971-976
24. Salminen E.K., Portin R.I., Koskinen A., Helenius H., and Nurmi M. Associations between serum testosterone fall and cognitive function in prostate cancer patients. Clin Cancer Res 10 (2004) 7575-7582
25. Salminen E.K., Portin R.I., Koskinen A.I., Helenius H.Y., and Nurmi M.J. Estradiol and cognition during androgen deprivation in men with prostate carcinoma. Cancer 103 (2005) 1381-1387
26. Taxel P., Stevens M.C., Trahiotis M., Zimmerman J., and Kaplan R.F. The effect of short-term estradiol therapy on cognitive function in older men receiving hormonal suppression therapy for prostate cancer. JAGS 52 (2004) 269-273
27. Joly F., Alibhai S.M.H., Galica J., Park A., Li Q.L., Wagner L., et al. Impact of androgen deprivation therapy on physical and cognitive function, as well as quality of life of patients with non metastatic prostate cancer. J Urol 176 (2006) 2443-2447
28. Cherrier M.M., Rose A.L., and Higano C. The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer. J Urol 170 (2003) 1808-1811
29. Jenkins V.A., Bloomfield D.J., Shilling V.M., and Edgington T.L. Does neoadjuvant hormone therapy for earlyprostate cancer affect cognition? Results from a pilot study. BJU Int 96 (2005) 48-53
30. Shahinian V.B., Kuo Y.F., Freeman J.L., and Goodwin J.S. Risk of the "androgen syndrome" in men receiving androgen deprivation for prostate cancer. Arch Inter Med 166 (2006) 465-471
31. Pirl W.F., Siegel G.I., Goode M.J., and Smith M.R. Depression in men receiving androgen deprivation therapy for prostate cancer: a pilot study. Psychooncology 11 (2002) 518-523
32. Nelson C.J., Lee J.S., Gamboa M.C., and Roth A.J. Cognitive effects of hormone therapy in men with prostate cancer: a review. Cancer 113 (2008) 1097-1106